- Home
- LRE vs BCTX Comparison
LRE vs BCTX Comparison
Compare LRE & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BCTX
- Stock Information
- Founded
- LRE 2001
- BCTX 2014
- Country
- LRE Japan
- BCTX Canada
- Employees
- LRE N/A
- BCTX N/A
- Industry
- LRE
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- BCTX Health Care
- Exchange
- LRE Nasdaq
- BCTX Nasdaq
- Market Cap
- LRE 20.5M
- BCTX 21.8M
- IPO Year
- LRE 2023
- BCTX N/A
- Fundamental
- Price
- LRE $1.63
- BCTX $12.44
- Analyst Decision
- LRE
- BCTX Strong Buy
- Analyst Count
- LRE 0
- BCTX 1
- Target Price
- LRE N/A
- BCTX $40.00
- AVG Volume (30 Days)
- LRE 133.7K
- BCTX 91.9K
- Earning Date
- LRE 01-01-0001
- BCTX 10-16-2025
- Dividend Yield
- LRE N/A
- BCTX N/A
- EPS Growth
- LRE N/A
- BCTX N/A
- EPS
- LRE N/A
- BCTX N/A
- Revenue
- LRE $110,330,328.00
- BCTX N/A
- Revenue This Year
- LRE N/A
- BCTX N/A
- Revenue Next Year
- LRE N/A
- BCTX $380.95
- P/E Ratio
- LRE N/A
- BCTX N/A
- Revenue Growth
- LRE 3.92
- BCTX N/A
- 52 Week Low
- LRE $1.00
- BCTX $6.00
- 52 Week High
- LRE $2.97
- BCTX $190.50
- Technical
- Relative Strength Index (RSI)
- LRE 51.88
- BCTX 56.17
- Support Level
- LRE $1.32
- BCTX $11.75
- Resistance Level
- LRE $1.74
- BCTX $14.68
- Average True Range (ATR)
- LRE 0.15
- BCTX 1.03
- MACD
- LRE 0.02
- BCTX -0.14
- Stochastic Oscillator
- LRE 57.40
- BCTX 42.86
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.